Alden Global Capital’s Pfizer PFE Stock Holding History

Alden Global Capital’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,500,000	Closed	-$43.2M	–	29
2023 Q4	$43.2M	Buy	+1,500,000	New	+$45.3M	17.96%	2

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

TIM

Thornburg Investment Management Santa Fe, New Mexico $9.63B AUM 35.65% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Alden Global Capital's PFE Position: Q1 2025 in Review

Alden Global Capital sold out of Pfizer (PFE) in Q1 2025, closing a stake of 234,525 shares — an estimated $6.22M sold.

Alden Global Capital first reported a position in PFE in Q4 2024 and held it in 1 quarter. The position peaked at $6.22M in Q4 2024. 2,930 funds tracked by Wall St. Rank hold PFE as of Q1 2025.

Alden Global Capital reported no remaining Pfizer position as of Q1 2025 after selling out during the quarter.
Alden Global Capital sold 234,525 Pfizer shares in Q1 2025, an estimated $6.22M.
Alden Global Capital first reported a position in Pfizer in Q4 2024 and held it in 1 quarter.
Alden Global Capital's Pfizer position peaked at $6.22M in Q4 2024.
2,930 funds tracked by Wall St. Rank held Pfizer as of Q1 2025.

Based on Alden Global Capital's 13F filing for Q1 2025, filed 15 May 2025.